<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33131137</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Co-incidental C9orf72 expansion mutation-related frontotemporal lobar degeneration pathology and sporadic Creutzfeldt-Jakob disease.</ArticleTitle><Pagination><StartPage>1009</StartPage><EndPage>1015</EndPage><MedlinePgn>1009-1015</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.14621</ELocationID><Abstract><AbstractText Label="BACKGROUND">The C9orf72 hexanucleotide expansion mutation is the most common cause of genetic frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS) and combined FTD-ALS. Its underlying neuropathology combines TDP-43 pathology and dipeptide repeat protein (DPR) deposits and may also associate with other neurodegeneration-associated protein aggregates. Herein we present a unique combination of C9orf72 mutation with sporadic Creutzfeldt-Jakob disease (CJD) in a 74-year-old patient with rapidly progressive dementia.</AbstractText><AbstractText Label="METHODS">Detailed neuropathological examination including immunohistochemistry for several proteinopathies. Genetic analysis was conducted by repeat primed polymerase chain reaction (PCR). Furthermore, we analyzed additional C9orf72 mutation carriers for prion-protein (PrP) deposits in brain tissue and screened the cerebellar cortex of other CJD cases for p62/DPR neuronal inclusions to assess the frequency of combined pathologies.</AbstractText><AbstractText Label="RESULTS">Postmortem brain examination of a patient with a rapidly progressive neurological deterioration of 8&#xa0;months' duration confirmed the diagnosis of CJD. She harbored valine homozygosity at PRNP codon 129. In addition, a frontotemporal lobar degeneration (FTLD)-pattern with TDP-43 protein aggregates and p62+/C9RANT+ positive inclusions along with a high degree of Alzheimer-related pathology (A3B3C3) were identified. The suspected C9orf72 expansion mutation was confirmed by repeat-primed PCR. Screening of 13 C9orf72 cases showed no pathological PrP aggregates and screening of 100 CJD cases revealed no other C9orf72 expansion mutation carriers.</AbstractText><AbstractText Label="CONCLUSION">A combination of a C9orf72 expansion mutation-related FTLD with sporadic CJD in the same patient is rare. While the rarity of both diseases makes this concurrence most likely to be coincidental, questions regarding a potential link between these two neurodegenerative pathologies deserve further studies.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. European Journal of Neurology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Klotz</LastName><ForeName>Sigrid</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3096-2852</Identifier><AffiliationInfo><Affiliation>Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Austrian Reference Center for Human Prion Diseases (OERPE), Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;nig</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erdler</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Klinik Donaustadt mit Ludwig-Boltzmann-Institut, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulram</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Krankenanstalt Rudolfstiftung, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Str&#xf6;bel</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Austrian Reference Center for Human Prion Diseases (OERPE), Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimprich</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St&#xf6;gmann</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regelsberger</LastName><ForeName>G&#xfc;nther</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Austrian Reference Center for Human Prion Diseases (OERPE), Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xf6;ftberger</LastName><ForeName>Romana</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budka</LastName><ForeName>Herbert</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Austrian Reference Center for Human Prion Diseases (OERPE), Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Gabor G</ForeName><Initials>GG</Initials><Identifier Source="ORCID">0000-0003-3841-5511</Identifier><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathobiology and Department of Medicine, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory Medicine Program &amp; Krembil Brain Institute, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelpi</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2948-4187</Identifier><AffiliationInfo><Affiliation>Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Austrian Reference Center for Human Prion Diseases (OERPE), Vienna, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007562" MajorTopicYN="Y">Creutzfeldt-Jakob Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">
C9orf72
</Keyword><Keyword MajorTopicYN="N">CJD</Keyword><Keyword MajorTopicYN="N">FTLD</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">prion</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>1</Day><Hour>20</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33131137</ArticleId><ArticleId IdType="pmc">PMC7898301</ArticleId><ArticleId IdType="doi">10.1111/ene.14621</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hsiung G&#x2010;YR, DeJesus&#x2010;Hernandez M, Feldman HH, et al. Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. Brain. 2012;135(3):709&#x2010;722. 10.1093/brain/awr354</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr354</ArticleId><ArticleId IdType="pmc">PMC3286328</ArticleId><ArticleId IdType="pubmed">22344582</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Frick P, Neumann M. The neuropathology associated with repeat expansions in the C9ORF72 gene. Acta Neuropathol. 2014;127(3):347&#x2010;357. 10.1007/s00401-013-1232-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1232-4</ArticleId><ArticleId IdType="pubmed">24356984</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck J, Poulter M, Hensman D, et al. Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet. 2013;92(3):345&#x2010;353. 10.1016/j.ajhg.2013.01.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2013.01.011</ArticleId><ArticleId IdType="pmc">PMC3591848</ArticleId><ArticleId IdType="pubmed">23434116</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindquist SG, Duno M, Batbayli M, et al. Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease. Clin Genet. 2013;83(3):279&#x2010;283. 10.1111/j.1399-0004.2012.01903.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-0004.2012.01903.x</ArticleId><ArticleId IdType="pubmed">22650353</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden JS, Rollinson S, Thompson JC, et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain. 2012;135(3):693&#x2010;708. 10.1093/brain/awr355</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr355</ArticleId><ArticleId IdType="pmc">PMC3286329</ArticleId><ArticleId IdType="pubmed">22300873</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart H, Rutherford NJ, Briemberg H, et al. Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p. Acta Neuropathol. 2012;123(3):409&#x2010;417. 10.1007/s00401-011-0937-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0937-5</ArticleId><ArticleId IdType="pmc">PMC3322555</ArticleId><ArticleId IdType="pubmed">22228244</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke C, Pomper JK, Biskup S, Pusk&#xe1;s C, Berg D, Synofzik M. Atypical parkinsonism in C9orf72 expansions: a case report and systematic review of 45 cases from the literature. J Neurol. 2016;263(3):558&#x2010;574. 10.1007/s00415-016-8021-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-016-8021-7</ArticleId><ArticleId IdType="pubmed">26810719</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper&#x2010;Knock J, Frolov A, Highley JR, et al. C9ORF72 expansions, Parkinsonism, and Parkinson disease a clinicopathologic study. Neurology. 2013;81(9):808&#x2010;811. 10.1212/WNL.0b013e3182a2cc38</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182a2cc38</ArticleId><ArticleId IdType="pmc">PMC3908460</ArticleId><ArticleId IdType="pubmed">23884045</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Yu JT, Zong Y, Zhou J, Tan L. C9ORF72 mutations in neurodegenerative diseases. Mol Neurobiol. 2014;49(1):386&#x2010;398. 10.1007/s12035-013-8528-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8528-1</ArticleId><ArticleId IdType="pubmed">23934648</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper&#x2010;Knock J, Shaw PJ, Kirby J. The widening spectrum of C9ORF72&#x2010;related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. Acta Neuropathol. 2014;127(3):333&#x2010;345. 10.1007/s00401-014-1251-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1251-9</ArticleId><ArticleId IdType="pmc">PMC3925297</ArticleId><ArticleId IdType="pubmed">24493408</ArticleId></ArticleIdList></Reference><Reference><Citation>Grau&#x2010;Rivera O, Gelpi E, Carballido&#x2010;L&#xf3;pez E, S&#xe1;nchez&#x2010;Valle R, L&#xf3;pez&#x2010;Villegas MD. Rapidly progressive dementia with psychotic onset in a patient with the C9ORF72 mutation. Clin Neuropathol. 2015; 34(5): 294&#x2013;197. 10.5414/NP300853.</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/NP300853</ArticleId><ArticleId IdType="pubmed">25943271</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PEA, Bieniek KF, Gendron TF, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77(4):639&#x2010;646. 10.1016/j.neuron.2013.02.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.02.004</ArticleId><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng S&#x2010;M, Arzberger T, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide&#x2010;repeat proteins in FTLD/ALS. Science (80&#x2010;). 2013;339(6125):1335&#x2010;1338. 10.1126/science.1232927</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232927</ArticleId><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos&#x2010;Campoy O, &#xc1;vila&#x2010;Polo R, Grau&#x2010;Rivera O, et al. Systematic screening of ubiquitin/p62 aggregates in cerebellar cortex expands the neuropathological phenotype of the C9orf72 expansion mutation. J Neuropathol Exp Neurol. 2018;77(8):703&#x2010;709. 10.1093/jnen/nly047</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nly047</ArticleId><ArticleId IdType="pubmed">29889265</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21&#x2010;linked ALS&#x2010;FTD. Neuron. 2011;72(2):257&#x2010;268. 10.1016/j.neuron.2011.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt&#x2010;Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol. 1999;46(2):224&#x2010;233. 10.1002/1531-8249(199908)46:2&lt;224:AID-ANA12&gt;3.0.CO;2-W</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(199908)46:2&lt;224:AID-ANA12&gt;3.0.CO;2-W</ArticleId><ArticleId IdType="pubmed">10443888</ArticleId></ArticleIdList></Reference><Reference><Citation>Parchi P, Strammiello R, Notari S, et al. Incidence and spectrum of sporadic Creutzfeldt&#x2010;Jakob disease variants with mixed phenotype and co&#x2010;occurrence of PrPSc types: an updated classification. Acta Neuropathol. 2009;118(5):659&#x2010;671. 10.1007/s00401-009-0585-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0585-1</ArticleId><ArticleId IdType="pmc">PMC2773124</ArticleId><ArticleId IdType="pubmed">19718500</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Neumann M, Baborie A, et al. A harmonized classification system for FTLD&#x2010;TDP pathology. Acta Neuropathol. 2011;122(1):111&#x2010;113. 10.1007/s00401-011-0845-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0845-8</ArticleId><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M. Reappraisal of TDP&#x2010;43 pathology in FTLD&#x2010;U subtypes. Acta Neuropathol. 2017;134(1):79&#x2010;96. 10.1007/s00401-017-1716-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1716-8</ArticleId><ArticleId IdType="pubmed">28466142</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M. Subcortical TDP&#x2010;43 pathology patterns validate cortical FTLD&#x2010;TDP subtypes and demonstrate unique aspects of C9orf72 mutation cases. Acta Neuropathol. 2020;139(1):83&#x2010;98. 10.1007/s00401-019-02070-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02070-4</ArticleId><ArticleId IdType="pubmed">31501924</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging&#x2010;Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123(1):1&#x2010;11. 10.1007/s00401-011-0910-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0910-3</ArticleId><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Ferrer I, Grinberg LT, et al. Aging&#x2010;related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol. 2016;131(1):87&#x2010;102. 10.1007/s00401-015-1509-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1509-x</ArticleId><ArticleId IdType="pmc">PMC4879001</ArticleId><ArticleId IdType="pubmed">26659578</ArticleId></ArticleIdList></Reference><Reference><Citation>Akimoto C, Volk AE, van Blitterswijk M, et al. A blinded international study on the reliability of genetic testing for GGGGCC&#x2010;repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories. J Med Genet. 2014;51(6):419&#x2010;424. 10.1136/jmedgenet-2014-102360</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2014-102360</ArticleId><ArticleId IdType="pmc">PMC4033024</ArticleId><ArticleId IdType="pubmed">24706941</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramm M, Schmitz M, Karch A, et al. Stability and reproducibility underscore utility of RT&#x2010;QuIC for diagnosis of Creutzfeldt&#x2010;Jakob disease. Mol Neurobiol. 2016;53(3):1896&#x2010;1904. 10.1007/s12035-015-9133-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9133-2</ArticleId><ArticleId IdType="pmc">PMC4789202</ArticleId><ArticleId IdType="pubmed">25823511</ArticleId></ArticleIdList></Reference><Reference><Citation>Worrall BB, Rowland LP, Chin SSM, Mastrianni JA. Amyotrophy in prion diseases. Arch Neurol. 2000;57(1):33 10.1001/archneur.57.1.33</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.57.1.33</ArticleId><ArticleId IdType="pubmed">10634430</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaguchi H, Takeuchi A, Horiuchi K, et al. Amyotrophic lateral sclerosis with frontotemporal dementia (ALS&#x2010;FTD) syndrome as a phenotype of Creutzfeldt&#x2010;Jakob disease (CJD)? A case report. J Neurol Sci. 2017;372:444&#x2010;446. 10.1016/j.jns.2016.10.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2016.10.038</ArticleId><ArticleId IdType="pubmed">27838004</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen C, Head MW, Rozemuller AJM, Ironside JW. Panencephalopathic Creutzfeldt&#x2010;Jakob disease in the Netherlands and the UK: clinical and pathological characteristics of nine patients. Neuropathol Appl Neurobiol. 2009;35(3):272&#x2010;282. 10.1111/j.1365-2990.2008.01004a.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.2008.01004a.x</ArticleId><ArticleId IdType="pubmed">19473294</ArticleId></ArticleIdList></Reference><Reference><Citation>Moussaud S, Jones DR, Moussaud&#x2010;Lamodi&#xe8;re EL, Delenclos M, Ross OA, McLean PJ. Alpha&#x2010;synuclein and tau: teammates in neurodegeneration? Mol Neurodegener. 2014;9(1):43 10.1186/1750-1326-9-43</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-9-43</ArticleId><ArticleId IdType="pmc">PMC4230508</ArticleId><ArticleId IdType="pubmed">25352339</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinton LK, Blurton&#x2010;Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic interactions between A&#x3b2;, tau, and &#x3b1;&#x2010;synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010;30(21):7281&#x2010;7289. 10.1523/JNEUROSCI.0490-10.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0490-10.2010</ArticleId><ArticleId IdType="pmc">PMC3308018</ArticleId><ArticleId IdType="pubmed">20505094</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Alafuzoff I, Al&#x2010;Sarraj S, et al. Mixed brain pathologies in dementia: the BrainNet Europe consortium experience. Dement Geriatr Cogn Disord. 2008;26:343&#x2010;350. 10.1159/000161560</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000161560</ArticleId><ArticleId IdType="pubmed">18849605</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimi J, Kovacs GG. Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther. 2014;6(9):82 10.1186/s13195-014-0082-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-014-0082-1</ArticleId><ArticleId IdType="pmc">PMC4239398</ArticleId><ArticleId IdType="pubmed">25419243</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieniek KF, Murray ME, Rutherford NJ, et al. Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. Acta Neuropathol. 2013;125(2):289&#x2010;302. 10.1007/s00401-012-1048-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1048-7</ArticleId><ArticleId IdType="pmc">PMC3551994</ArticleId><ArticleId IdType="pubmed">23053135</ArticleId></ArticleIdList></Reference><Reference><Citation>Grau&#x2010;Rivera O, Gelpi E, Nos C, et al. Clinicopathological correlations and concomitant pathologies in rapidly progressive dementia: a brain bank series. Neurodegener Dis. 2015;15(6):350&#x2010;360. 10.1159/000439251</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000439251</ArticleId><ArticleId IdType="pubmed">26523804</ArticleId></ArticleIdList></Reference><Reference><Citation>Hainfellner JA, Wanschitz J, Jellinger K, Liberski PP, Gullotta F, Budka H. Coexistence of Alzheimer&#x2010;type neuropathology in Creutzfeldt&#x2010;Jakob disease. Acta Neuropathol. 1998;96(2):116&#x2010;122. 10.1007/s004010050870</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010050870</ArticleId><ArticleId IdType="pubmed">9705125</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi M, Kai H, Baiardi S, et al. The characterization of AD/PART co&#x2010;pathology in CJD suggests independent pathogenic mechanisms and no cross&#x2010;seeding between misfolded A&#x3b2; and prion proteins. Acta Neuropathol Commun. 2019;7(1):53 10.1186/s40478-019-0706-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0706-6</ArticleId><ArticleId IdType="pmc">PMC6454607</ArticleId><ArticleId IdType="pubmed">30961668</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Rahimi J, Str&#xf6;bel T, et al. Tau pathology in Creutzfeldt&#x2010;Jakob disease revisited. Brain Pathol. 2017;27(3):332&#x2010;344. 10.1111/bpa.12411</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12411</ArticleId><ArticleId IdType="pubmed">27377321</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Staging of Alzheimer's disease&#x2010;related neurofibrillary changes. Neurobiol Aging. 1995;16(3):271&#x2010;278. 10.1016/0197-4580(95)00021-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(95)00021-6</ArticleId><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiniger L, Lukic A, Linehan J, et al. Tau, prions and A&#x3b2;: the triad of neurodegeneration. Acta Neuropathol. 2011;121(1):5&#x2010;20. 10.1007/s00401-010-0691-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0691-0</ArticleId><ArticleId IdType="pmc">PMC3015202</ArticleId><ArticleId IdType="pubmed">20473510</ArticleId></ArticleIdList></Reference><Reference><Citation>Laur&#xe9;n J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid&#x2010;&#x392; oligomers. Nature. 2009;457(7233):1128&#x2010;1132. 10.1038/nature07761</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07761</ArticleId><ArticleId IdType="pmc">PMC2748841</ArticleId><ArticleId IdType="pubmed">19242475</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox TO, Gunther EC, Brody AH, et al. Anti&#x2010;PrPC antibody rescues cognition and synapses in transgenic Alzheimer mice. Ann Clin Transl Neurol. 2019;6(3):554&#x2010;574. 10.1002/acn3.730</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.730</ArticleId><ArticleId IdType="pmc">PMC6414488</ArticleId><ArticleId IdType="pubmed">30911579</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador&#x2010;Ortiz C, Lin WL, Ahmed Z, et al. TDP&#x2010;43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol. 2007;61(5):435&#x2010;445. 10.1002/ana.21154</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21154</ArticleId><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Whitwell JL, et al. Updated TDP&#x2010;43 in Alzheimer's disease staging scheme. Acta Neuropathol. 2016;131(4):571&#x2010;585. 10.1007/s00401-016-1537-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1537-1</ArticleId><ArticleId IdType="pmc">PMC5946692</ArticleId><ArticleId IdType="pubmed">26810071</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima&#x2010;Yasuda H, Uryu K, Robinson J, et al. Co&#x2010;morbidity of TDP&#x2010;43 proteinopathy in Lewy body related diseases. Acta Neuropathol. 2007;114(3):221&#x2010;229. 10.1007/s00401-007-0261-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0261-2</ArticleId><ArticleId IdType="pubmed">17653732</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Mackenzie IRA, Hasegawa M, et al. Phosphorylated TDP&#x2010;43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol. 2009;117(2):125&#x2010;136. 10.1007/s00401-008-0480-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0480-1</ArticleId><ArticleId IdType="pubmed">19139911</ArticleId></ArticleIdList></Reference><Reference><Citation>Colom&#x2010;Cadena M, Grau&#x2010;Rivera O, Planellas L, et al. Regional overlap of pathologies in Lewy body disorders. J Neuropathol Exp Neurol. 2017;76(3):216&#x2010;224. 10.1093/jnen/nlx002</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlx002</ArticleId><ArticleId IdType="pubmed">28395086</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga S, Lin WL, Walton RL, Ross OA, Dickson DW. TDP&#x2010;43 pathology in multiple system atrophy: colocalization of TDP&#x2010;43 and &#x3b1;&#x2010;synuclein in glial cytoplasmic inclusions. Neuropathol Appl Neurobiol. 2018;44(7):707&#x2010;721. 10.1111/nan.12485</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12485</ArticleId><ArticleId IdType="pmc">PMC6191374</ArticleId><ArticleId IdType="pubmed">29660838</ArticleId></ArticleIdList></Reference><Reference><Citation>Miguelez&#x2010;Rodriguez A, Santos&#x2010;Juanes J, Vicente&#x2010;Etxenausia I, et al. Brains with sporadic Creutzfeldt&#x2010;Jakob disease and copathology showed a prolonged end&#x2010;stage of disease. J Clin Pathol. 2018;71(5):446&#x2010;450. 10.1136/jclinpath-2017-204794</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jclinpath-2017-204794</ArticleId><ArticleId IdType="pubmed">29097599</ArticleId></ArticleIdList></Reference><Reference><Citation>Isaacs AM, Powell C, Webb TE, Linehan JM, Collinge J, Brandner S. Lack of TAR&#x2010;DNA binding protein&#x2010;43 (TDP&#x2010;43) pathology in human prion diseases. Neuropathol Appl Neurobiol. 2008;34(4):446&#x2010;456. 10.1111/j.1365-2990.2008.00963.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.2008.00963.x</ArticleId><ArticleId IdType="pmc">PMC2607533</ArticleId><ArticleId IdType="pubmed">18657254</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>